Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup.

被引：0
|
作者：
Cislo, Paul
Reuning-Scherer, Jonathan D.
机构：
[1] Bayer HealthCare, Whippany, NJ USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of radium-223 dichloride (Ra-223) on pain from US EAP.
    Morris, Michael J.
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Shore, Neal D.
    Cislo, Paul
    Bangerter, Keith
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] Effect of radium-223 dichloride (Ra-223) on pain from US EAP.
    Sweeney, Christopher
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Shore, Neal D.
    Cislo, Paul
    Bangerter, Keith
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Effect of radium-233 dichloride (Ra-223) on hospitalization and its economic implications in ALSYMPCA trial
    Parker, C.
    Zhan, L.
    Cislo, P.
    Reuning-Scherer, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S183 - S183
  • [4] Radium-223 dichloride (Ra-223) in US expanded access program (EAP).
    Vogelzang, Nicholas J.
    Fernandez, Daniel Celestino
    Morris, Michael J.
    Iagaru, Andrei
    Brown, Alan
    Almeida, Fabio
    Sweeney, Christopher
    Smith, Matthew Raymond
    Dicker, Adam
    Wong, Yu-Ning
    Shore, Neal D.
    Bangerter, Keith
    Petrenciuc, Oana
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] Impact of Prior Docetaxel, Extent of Disease (EOD), and Prior Bisphosphonates (Bp) on Hematologic (Heme) Safety of Radium-223 Dichloride (Ra-223) From ALSYMPCA
    Michalski, J. M.
    Parker, C.
    Sartor, O.
    Vogelzang, N.
    Haugen, I.
    Wahba, M.
    Nilsson, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S441 - S442
  • [6] Impact of prior docetaxel, Extent of Disease (EOD), and prior Bisphosphonates (Bp) on Hematologic (Heme) safety of radium-223 Dichloride (Ra-223) from ALSYMPCA
    Strauss, A.
    Michalski, J. M.
    Parker, C.
    Sartor, O.
    Vogelzang, N. J.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 81 - 81
  • [7] Chemotherapy Following Radium-223 Dichloride Treatment in ALSYMPCA
    Sartor, Oliver
    Hoskin, Peter
    Coleman, Robert E.
    Nilsson, Sten
    Vogelzang, Nicholas J.
    Petrenciuc, Oana
    Staudacher, Karin
    Thuresson, Marcus
    Parker, Christopher
    PROSTATE, 2016, 76 (10): : 905 - 916
  • [8] Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial
    Parker, Christopher
    Zhan, Lin
    Cislo, Paul
    Reuning-Scherer, Jonathan
    Vogelzang, Nicholas J.
    Nilsson, Sten
    Sartor, Oliver
    O'Sullivan, Joe M.
    Coleman, Robert E.
    EUROPEAN JOURNAL OF CANCER, 2017, 71 : 1 - 6
  • [9] Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes
    Sartor, A. Oliver
    Amariglio, Roy
    Wilhelm, Scott
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Fang, Fang
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (HRQoL) assessed by the EQ-5D utility scores in ALSYMPCA
    Stroelin, P.
    Cislo, P.
    Sartor, O.
    Reuning-Scherer, J.
    Shan, M.
    Zhan, L.
    Parker, C.
    Oncology Research and Treatment, 2015, 38 : 82 - 82
12345